Author ORCID Identifier
N/A
N/A
N/A
N/A
https://orcid.org/0000-0003-1583-2056
https://orcid.org/0000-0002-0543-9149
https://orcid.org/0000-0001-6277-9310
N/A
N/A
https://orcid.org/0000-0001-9794-8137
N/A
N/A
N/A
N/A
N/A
Document Type
Article
Publication Date
2019
College/Unit
School of Medicine
Department/Program/Center
Microbiology, Immunology, and Cell Biology
Abstract
Current acellular pertussis vaccines fall short of optimal protection against the human respiratory pathogen Bordetella pertussis resulting in increased incidence of a previously controlled vaccine- preventable disease. Natural infection is known to induce a protective mucosal immunity. Therefore, in this study, we aimed to use acellular pertussis vaccines to recapitulate these mucosal immune responses. We utilized a murine immunization and challenge model to characterize the efficacy of intranasal immunization (IN) with DTaP vaccine or DTaP vaccine supplemented with curdlan, a known Th1/Th17 promoting adjuvant. Protection from IN delivered DTaP was compared to protection mediated by intraperitoneal injection of DTaP and whole-cell pertussis vaccines. We tracked fluorescently labeled DTaP after immunization and detected that DTaP localized preferentially in the lungs while DTaP with curdlan was predominantly in the nasal turbinates. IN immunization with DTaP, with or without curdlan adjuvant, resulted in anti-B. pertussis and anti-pertussis toxin IgG titers at the same level as intraperitoneally administered DTaP. IN immunization was able to protect against B. pertussis challenge and we observed decreased pulmonary pro-inflammatory cytokines, neutrophil infiltrates in the lung, and bacterial burden in the upper and lower respiratory tract at day 3 post challenge. Furthermore, IN immunization with DTaP triggered mucosal immune responses such as production of B. pertussis-specific IgA, and increased IL-17A. Together, the induction of a mucosal immune response and humoral antibody-mediated protection associated with an IN administered DTaP and curdlan adjuvant warrant further exploration as a pertussis vaccine candidate formulation.
Digital Commons Citation
Boehm, Dylan T.; Wolf, M. Allison; Hall, Jesse M.; Wong, Ting Y.; Sen-Kilic, Emel; Basinger, Hayden D.; Dziadowicz, Sebastian A.; Gutierrez, Maria de la Paz; Blackwood, Catherine B.; Bradford, Shelby D.; Begley, Katherine A.; Witt, William T.; Varney, Melinda E.; Barbier, Mariette; and Damron, F. Heath, "Intranasal Acellular Pertussis Vaccine Provides Mucosal Immunity and Protects Mice from Bordetella Pertussis" (2019). Faculty & Staff Scholarship. 1579.
https://researchrepository.wvu.edu/faculty_publications/1579
Source Citation
Boehm, D. T., Wolf, M. A., Hall, J. M., Wong, T. Y., Sen-Kilic, E., Basinger, H. D., Dziadowicz, S. A., Gutierrez, M. de la P., Blackwood, C. B., Bradford, S. D., Begley, K. A., Witt, W. T., Varney, M. E., Barbier, M., & Damron, F. H. (2019). Intranasal acellular pertussis vaccine provides mucosal immunity and protects mice from Bordetella pertussis. Npj Vaccines, 4(1). https://doi.org/10.1038/s41541-019-0136-2
Comments
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/.